PMID- 35294302
OWN - NLM
STAT- MEDLINE
DCOM- 20220318
LR  - 20220318
IS  - 2768-3613 (Electronic)
IS  - 2768-3605 (Linking)
VI  - 28
IP  - 3
DP  - 2022 Mar
TI  - Efficacy and Safety of Eucalyptus for Relieving Cough: A Systematic Review and 
      Meta-Analysis of Randomized Controlled Trials.
PG  - 218-226
LID - 10.1089/jicm.2021.0226 [doi]
AB  - Objectives: To assess the efficacy and safety of Eucalyptus globulus Labill 
      (Eucalyptus) on cough. Background: Cough is a common symptom of upper respiratory 
      tract infections (URTIs) and bronchitis. Eucalyptus products are frequently used 
      as over-the-counter cough medications but their efficacy and safety are 
      uncertain. Methods: Randomized controlled trials (RCTs) investigating efficacy 
      and safety of Eucalyptus for cough were systematically searched in electronic 
      databases till February 2021. Two reviewers independently performed study 
      selection, data extraction, and quality assessment. Clinical outcomes including 
      improvement or resolution of overall cough symptoms, cough frequency (CF), and 
      adverse events (AEs) of Eucalyptus were evaluated and analyzed using a 
      random-effects model. Heterogeneity was evaluated using I(2) and chi-squared 
      test. Results: Six RCTs with 1,857 participants with cough were included in this 
      study. Most of the included studies used Eucalyptus in combination formula (four 
      of six studies). Based on Cochrane's risk of bias criteria, three of six studies 
      (50%) were rated low risk of bias, whereas the remaining were judged as high risk 
      of bias. This study found that Eucalyptus products are more effective than 
      placebo in terms of improvement or resolution of overall cough symptoms with 
      relative risk 1.45 (95% confidence interval (95% CI) 1.26-1.67). Whereas all 
      Eucalyptus formulae reduced CF with weighted mean difference 0.44 (95% CI 
      0.28-0.60), when compared with placebo. There are no serious AEs associated with 
      Eucalyptus during treatment periods. Mild-to-moderate gastrointestinal symptoms 
      were common AEs reported in a comparable study between Eucalyptus and control 
      groups. Conclusion: The findings indicate that Eucalyptus products are safe for 
      use in cough related to respiratory diseases such as URTIs and bronchitis. 
      However, their efficacy is minimal and of uncertain clinical importance. Further 
      high-quality studies are still necessary to confirm this finding.
FAU - Her, Ladda
AU  - Her L
AD  - Department of Clinical Pharmacy, Faculty of Pharmacy, Mahasarakham University, 
      Maha Sarakham, Thailand.
FAU - Kanjanasilp, Juntip
AU  - Kanjanasilp J
AD  - Clinical Trials and Evidence-Based Syntheses Research Unit (CTEBs RU), Faculty of 
      Pharmacy, Mahasarakham University, Maha Sarakham, Thailand.
FAU - Chaiyakunapruk, Nathorn
AU  - Chaiyakunapruk N
AD  - College of Pharmacy, University of Utah, Salt Lake City, UT, USA.
FAU - Sawangjit, Ratree
AU  - Sawangjit R
AUID- ORCID: 0000-0002-6868-4336
AD  - Clinical Trials and Evidence-Based Syntheses Research Unit (CTEBs RU), Faculty of 
      Pharmacy, Mahasarakham University, Maha Sarakham, Thailand.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20220117
PL  - United States
TA  - J Integr Complement Med
JT  - Journal of integrative and complementary medicine
JID - 9918283075806676
SB  - IM
MH  - *Bronchitis/drug therapy
MH  - Cough/drug therapy
MH  - *Eucalyptus
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - *Respiratory Tract Infections/drug therapy
OTO - NOTNLM
OT  - Eucalyptus globulus Labill
OT  - cough
OT  - eucalyptus
OT  - herbal medicine
OT  - safety
OT  - systematic review
EDAT- 2022/03/17 06:00
MHDA- 2022/03/19 06:00
CRDT- 2022/03/16 17:15
PHST- 2022/03/16 17:15 [entrez]
PHST- 2022/03/17 06:00 [pubmed]
PHST- 2022/03/19 06:00 [medline]
AID - 10.1089/jicm.2021.0226 [doi]
PST - ppublish
SO  - J Integr Complement Med. 2022 Mar;28(3):218-226. doi: 10.1089/jicm.2021.0226. 
      Epub 2022 Jan 17.